Microbiology · 2010 · 36 citations · 16 references
Life SciencesMedicinal ChemistryPharmacologyAntimicrobial PharmacologyAntimicrobial ResistanceChemotherapyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsEfflux-mediated ResistanceMultidrug ResistanceResistance In Gram-negative BacteriaBacterial Efflux PumpsBacterial Multidrug ResistanceDrug Efflux PumpsEfflux Pump-mediated ResistanceIntracellular Drug ConcentrationMultidrug Efflux PumpsMultidrug-resistant Gram-negative BacteriaMultidrug-resistant Organisms
To date, various bacterial drug efflux pump inhibitors (EPIs) have been described. They exhibit variability in their activity spectrum with respect to antibiotic structural class and bacterial species. Among the various 4-alkylaminoquinazoline derivatives synthesized and studied in this work, one molecule, 1167, increased the susceptibility of important human-pathogenic, resistant, Gram-negative bacteria towards different antibiotic classes. This 4-(3-morpholinopropylamino)-quinazoline induced an increase in the activity of chloramphenicol, nalidixic acid, norfloxacin and sparfloxacin, which are substrates of the AcrAB-TolC and MexAB-OprM efflux pumps that act in these multidrug-resistant isolates. In addition, 1167 increased the intracellular concentration of chloramphenicol in efflux pump-overproducing strains. The rate of restoration depended on the structure of the antibiotic, suggesting that different sites in the efflux pumps may be involved. A molecule exhibiting a morpholine functional group and a propyl extension of the side chain was more active.
16
Structural Basis of Multiple Drug-Binding Capacity of the AcrB Multidrug Efflux Pump
Edward Yu, Gerry McDermott, Helen I. Zgurskaya et al. · Science · 2003 · 392 citations
Yumiko Takatsuka, Cheng Chen, Hiroshi Nikaido · Proceedings of the National Academy of Sciences · 2010 · 191 citations · Full text